论文部分内容阅读
目的探讨放化疗同步治疗胃癌根治术后腹腔淋巴结转移瘤的临床疗效及安全性。方法选取攀枝花市第六人民医院2015年10月—2016年4月收治的胃癌根治术后腹腔淋巴结转移瘤患者82例,随机分为对照组和观察组,每组41例。对照组患者仅采取放射治疗,观察组患者在对照组基础上给予替吉奥胶囊。比较两组患者的临床疗效及骨髓抑制、肝功能受损、放射性肠炎、恶心呕吐发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。两组患者骨髓抑制、肝功能受损、放射性肠炎、恶心呕吐发生率比较,差异无统计学意义(P>0.05)。结论放化疗同步治疗胃癌根治术后腹腔淋巴结转移瘤的临床疗效确切,且安全性好。
Objective To investigate the clinical efficacy and safety of concurrent chemoradiotherapy in the treatment of abdominal lymph node metastases after radical operation of gastric cancer. Methods 82 cases of patients with celiac lymph node metastases after radical gastrectomy of gastric cancer treated in Panzhihua Sixth People’s Hospital from October 2015 to April 2016 were randomly divided into control group and observation group with 41 cases in each group. Patients in the control group were treated with radiotherapy only. Patients in the observation group were given tigeorgile capsules on the basis of the control group. The clinical efficacy, bone marrow suppression, impaired liver function, radiation enteritis and nausea and vomiting were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). There was no significant difference in the incidence of bone marrow suppression, impaired liver function, radiation enteritis and nausea and vomit between the two groups (P> 0.05). Conclusions The concurrent chemoradiotherapy with chemoradiotherapy for gastric cancer with celiac lymphnode metastases is effective and safe.